Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 phase II dose-ranging trial in NASH with fibrosis
2020-002723-11Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing BI 456906 dose-ranging arms with Placebo (2 arms). Primary endpoint: Improvement in liver histological findings. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2020-002723-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002723-11.